


R&D Pipeline

Daiichi Sankyo Group Research & Development Pipeline (Development Stage)

February 2008
DAIICHI SANKYO CO., LTD.

Therapeutic Area	Main Existing Product	Phase1	Phase2	Phase3	Application/Approval
Cardiovascular diseases	Mevalotin Benicar / Olmetec Azor Welchol Olmotec Calblock Artist Mevalotin Kremezin Harp Livalo Sunrythm Beprior	DZ-897b(US/EU/JP) (anti-platelet agent) HGF DNA therapy(US/EU) (coronary arterial diseases) DB-772d(US/EU) (oral factor Xa inhibitor) CS-8080(US/EU) (anti-arteriosclerosis)	DU-178b(US/EU/JP) (oral factor Xa inhibitor) HGF DNA therapy(US/EU) (peripheral arterial diseases) SUN 4936h(US/EU) (acute heart failure/ during license activity) ★CS-866DM(JP) (diabetic nephropathy) ★CS-866AZ(JP) (Olmесartan/Azelnidipine combination) CS-747(JP) (anti-platelet agent)	 HGF DNA therapy(JP) (peripheral arterial diseases) ★CS-866DM(JP) (diabetic nephropathy) ★CS-866AZ(JP) (Olmесartan/Azelnidipine combination) <u>★CS-8635(US)</u> (Olmесartan/Hydrochlorothiazide/Amlodipine combination)	CS-747(EU) (anti-platelet agent/application) CS-747(US) (anti-platelet agent/application) ★CS-8663(EU) (Olmесartan/Amlodipine combination/application)
Glucose metabolic disorders	Fastic	SUN E7001(JP) (anti-type II diabetic/ during license activity) AJD101(US/EU) (activation of the insulin signaling pathway)	CS-011(JP) (antidiabetic/glitazone type) AJD101(JP) (activation of the insulin signaling pathway)	CS-011(US/EU) (antidiabetic/glitazone type)	
Infectious diseases	Levaquin / Tavanic Banan Cravit	DC-159a(US/EU) (new quinolone) CS-8958(US/EU) (anti-influenza/co-development with Biota)	DU-8859a inj(US) (new quinolone) CS-023(US/EU/JP) (carbapenem-type antibiotic) CS-8958(JP) (anti-influenza)	SUN A0028(North America) (penem-type antibiotic/licensed-out to Replidyne) ★levofloxacin inj(JP) (new quinolone)	DF-098(JP) (Hib vaccine/approval) DU-8859a oral(JP) (new quinolone/approval) ★levofloxacin high-dose(JP) (new quinolone/application)
Cancer	Camptosar Topotecin Krestin	CS-7017(US/EU) (PPAR γ activator) DE-788(JP) (nimotuzumab/anti-EGFR antibody)	CS-1008(US/EU) (anti-DR5 antibody)		
Immunological allergic diseases	Zyrtec	CS-0777(US/EU) (immunomodulator)			
Bone/Joint diseases	Loxonin Mobic		SUN E3001(JP) (osteoporosis/during license activity)	AMG182(JP) (denosumab/ anti-RANKL antibody/ P3; bone metastases of cancer, P2; osteoporosis) ★CS-800G(JP) (loxoprofen gel)	★LX-P(JP) (loxoprofen tape/application/ co-development with Lead Chemical)
Others	Venofer Evoxac Omnipaque Omniscan Feron Urief	SUN N8075(US/EU) (neuroprotectant/licensed-out to Cecoura)	SUN N4057(US/EU) (acute ischemic stroke) CS-088(US/EU/JP) (antiglaucoma/co-development with Santen) SUN11031(JP) (anorexia nervosa) SUN11031(US/EU) (cachexia)	SUN Y7017(JP) (mild to moderate and severe dementia of Alzheimer type) KMD-3213(China) (treatment of dysuria associated with benign prostatic hyperplasia)	SUN 0588r(US/EU/JP) (EU:hyperphenylalaninemia/ licensed-out to BioMarin/application, JP:BH4 responsive hyperphenylalaninemia/application) ★DL-8234(JP) (Feron add indic./hepatitis C/with Ribavirin/application)

★additional indications, new formulations etc.

Change from the announcement of January 2008

New(underline) : CS-8635(US)
Change of Stage etc. : CS-747(EU)